Causaly, an AI platform for biomedical research, has closed a £46 million round of Series B funding. Developing a new drug is an arduous process that typically spans over a decade, involving extensive research, development and rigorous clinical trials. There is real urgency to expedite this process for the most complex and unsolved diseases of … Continue reading £46m boost for AI MedTech Causaly